Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week

NCT00431561 is registered in ClinicalTrials.gov with Isarna Therapeutics GmbH as lead sponsor.

NCT NCT00431561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00431561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week
Lead sponsor
Isarna Therapeutics GmbH
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2003
Completion date
March 31, 2009
Enrollment
141 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, glioblastoma